Regorafenib Deemed Not Cost-Effective for Metastatic CRC

This article originally appeared here.
Share this content:
Regorafenib Deemed Not Cost-Effective for Metastatic CRC
Regorafenib Deemed Not Cost-Effective for Metastatic CRC

MONDAY, Sept. 21, 2015 (HealthDay News) -- Given its high cost, regorafenib provides little added benefit as a third-line treatment for metastatic colorectal cancer, according to a study published online Aug. 24 in the Journal of Clinical Oncology.

Daniel A. Goldstein, M.D., from Emory University in Atlanta, and colleagues developed a Markov model to compare the cost-effectiveness of regorafenib with that of a placebo in the third-line treatment of metastatic colorectal cancer. Medicare 2014 reimbursement rates were used to assess drug costs.

The researchers found that regorafenib provided an additional 0.04 quality-adjusted life-years (QALYs) (0.13 life-years) at a cost of $40,000, resulting in an incremental cost-effectiveness ratio of $900,000 per QALY. In univariable and probabilistic sensitivity analyses, the incremental cost-effectiveness ratio for regorafenib was >$550,000 per QALY.

"Regorafenib provides minimal incremental benefit at high incremental cost per QALY in the third-line management of metastatic colorectal cancer," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »